Predictive markers in elderly patients with estrogen receptor-positive breast cancer treated with aromatase inhibitors: an array-based pharmacogenetic study

[1]  P. Neven,et al.  CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1–98 trial , 2015, Breast Cancer Research and Treatment.

[2]  Jian-hua Zhou,et al.  A Polymorphism at the 3′-UTR Region of the Aromatase Gene Is Associated with the Efficacy of the Aromatase Inhibitor, Anastrozole, in Metastatic Breast Carcinoma , 2013, International journal of molecular sciences.

[3]  Mario Cannataro,et al.  DMET-Analyzer: automatic analysis of Affymetrix DMET Data , 2012, BMC Bioinformatics.

[4]  S. Marsh,et al.  Pharmacogenomics of third-generation aromatase inhibitors , 2012, Expert opinion on pharmacotherapy.

[5]  W. Newman,et al.  Pharmacogenetics of aromatase inhibitors. , 2012, Pharmacogenomics.

[6]  A. Howell,et al.  Polymorphisms of CYP19A1 and response to aromatase inhibitors in metastatic breast cancer patients , 2012, Breast Cancer Research and Treatment.

[7]  Lang Li,et al.  Plasma Letrozole Concentrations in Postmenopausal Women With Breast Cancer Are Associated With CYP2A6 Genetic Variants, Body Mass Index, and Age , 2011, Clinical pharmacology and therapeutics.

[8]  B. Nam,et al.  Single nucleotide polymorphisms of CYP19A1 predict clinical outcomes and adverse events associated with letrozole in patients with metastatic breast cancer , 2011, Cancer Chemotherapy and Pharmacology.

[9]  D. Rea,et al.  Systematic review of aromatase inhibitors in the first-line treatment for hormone sensitive advanced or metastatic breast cancer , 2010, Breast Cancer Research and Treatment.

[10]  M. Climent,et al.  A polymorphism at the 3'-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozole , 2010, BMC Cancer.

[11]  L. Gibson,et al.  Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. , 2007, The Cochrane database of systematic reviews.

[12]  Mitch Dowsett,et al.  Emerging Biomarkers and New Understanding of Traditional Markers in Personalized Therapy for Breast Cancer , 2008, Clinical Cancer Research.

[13]  M. Ellis,et al.  Aromatase expression and outcomes in the P024 neoadjuvant endocrine therapy trial , 2008, Breast Cancer Research and Treatment.

[14]  Philip S Rosenberg,et al.  PGA: power calculator for case-control genetic association analyses , 2008, BMC Genetics.

[15]  J. Forbes,et al.  Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  B. Lloveras,et al.  A Single-Nucleotide Polymorphism in the Aromatase Gene Is Associated with the Efficacy of the Aromatase Inhibitor Letrozole in Advanced Breast Carcinoma , 2008, Clinical Cancer Research.

[17]  T. Whelan,et al.  Clinical outcomes of ethnic minority women in MA.17: a trial of letrozole after 5 years of tamoxifen in postmenopausal women with early stage breast cancer. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  Joan Valls,et al.  SNPStats: a web tool for the analysis of association studies , 2006, Bioinform..

[19]  Eric D Wieben,et al.  Human aromatase: gene resequencing and functional genomics. , 2005, Cancer research.

[20]  M. Piccart,et al.  Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  N. Davidson,et al.  The biology of breast carcinoma , 2003, Cancer.

[22]  S. Glück.  Anastrozole Is Superior to Tamoxifen as First-Line Therapy in Hormone Receptor Positive Advanced Breast Carcinoma Results of Two Randomized Trials Designed for Combined Analysis , 2001 .

[23]  A. Buzdar,et al.  Anastrozole is superior to tamoxifen as first‐line therapy in hormone receptor positive advanced breast carcinoma , 2001, Cancer.

[24]  C. Boni,et al.  Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  M. Brandi,et al.  Polymorphism of the aromatase gene in postmenopausal Italian women: distribution and correlation with bone mass and fracture risk. , 2001, The Journal of clinical endocrinology and metabolism.

[26]  B. Fridley,et al.  Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors. , 2010, Cancer research.